Metal Containing, E.g., Chromoproteins, Ferritin, Ferredoxins, Etc. Patents (Class 530/400)
  • Patent number: 8575095
    Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-1 entry inhibitor candidate.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 5, 2013
    Assignee: Philadelphia Health & Education Corporation
    Inventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
  • Publication number: 20130289253
    Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 31, 2013
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
  • Publication number: 20130289252
    Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.
    Type: Application
    Filed: February 20, 2013
    Publication date: October 31, 2013
    Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Jonathan A. WINGER, Michael A. MARLETTA
  • Publication number: 20130280173
    Abstract: The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging.
    Type: Application
    Filed: April 4, 2013
    Publication date: October 24, 2013
    Inventors: Michal NEEMAN, Raz Zarivach, Marina Radoul, Batya Cohen, Moriel Vandsburger, Limor Lewin
  • Patent number: 8551945
    Abstract: Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: October 8, 2013
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Carolyn Dent, Josee Laganiere, Xiangdong Meng, David Paschon, Siyuan Tan, Lei Zhang, Steve H. Zhang
  • Patent number: 8541245
    Abstract: The present invention provides methods and kits for assessing the state of oocyte maturation in a female mammal based on the level of PAPP-A found in the female's bodily fluid sample.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: September 24, 2013
    Assignee: Beckman Coulter, Inc.
    Inventor: William E. Roudebush
  • Publication number: 20130245240
    Abstract: Provided is a bio-hybrid material that does not cause elution of nickel ions and has an excellent endothelialization ability, a production method therefor, and a stent. The bio-hybrid material (101) used includes an alloy part (11) free of Ni, an organic acid (12) having two or more active esters, and a cytokine (13). The alloy part (11) free of Ni forms an ester bond with the organic acid (12), and the organic acid (12) and the cytokine (13) are immobilized via an amide bond.
    Type: Application
    Filed: November 24, 2011
    Publication date: September 19, 2013
    Applicant: NATIONAL INSTITUTE FOR MATERIALS SCIENCE
    Inventors: Tetsushi Taguchi, Makoto Sasaki, Yasuyuki Katada
  • Publication number: 20130244955
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.
    Type: Application
    Filed: August 16, 2011
    Publication date: September 19, 2013
    Inventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
  • Patent number: 8536314
    Abstract: The present invention provides variants of fluorescent proteins, which are improved with regard to their properties for use as reporter proteins and/or in analytics. In particular, variants of fluorescent proteins are provided, which fluoresce brighter, show improved quantum yield and/or have shifted excitation or emission spectra. The fluorescent proteins according to the invention comprise in their LOV domain besides the substitution of a cysteine with an amino acid that does not covalently bind FMN at least one further point mutation.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: September 17, 2013
    Assignee: Evocatal GmbH
    Inventors: Thorsten Eggert, Sascha Hausmann, Michael Puls
  • Publication number: 20130239238
    Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 12, 2013
    Applicant: JANSSEN BIOTECH INC.
    Inventors: Robert Jordan, David Knight, Randall Brezski, Mary Ryan, Diane Petrone
  • Patent number: 8522984
    Abstract: There is provided a filter for filtering gas or liquid, wherein a constituent material of the filter contains a protein that absorbs iron, radium, or heavy metal (except iron), the constituent material is an iron-containing fiber body 4, the iron-containing fiber body 4 is a fiber body including iron or a fiber body 41 on which iron is supported, and the protein is ferritin or hemosiderin and bound to iron of the iron-containing fiber body 4.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: September 3, 2013
    Assignee: National University Corporation Okayama University
    Inventor: Eizo Nakamura
  • Publication number: 20130210731
    Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 15, 2013
    Applicant: The Board of Trustees of the University of Illinois
    Inventor: The Board of Trustees of the University of Illinois
  • Publication number: 20130177983
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Application
    Filed: September 21, 2012
    Publication date: July 11, 2013
    Applicant: Sangamo BioScience, Inc.
    Inventor: Sangamo BioScience, Inc.
  • Publication number: 20130171071
    Abstract: The present invention relates to imidazolium salts, particularly imidazolium salts of the general formula I as well as the respective carbene metal complexes and their utilisation as bioanalytical tags for biomolecules.
    Type: Application
    Filed: September 5, 2011
    Publication date: July 4, 2013
    Applicant: ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD
    Inventor: Olaf Kuehl
  • Publication number: 20130172204
    Abstract: The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma.
    Type: Application
    Filed: April 13, 2011
    Publication date: July 4, 2013
    Applicant: M-LAB AG
    Inventors: Franz Grus, Nils Boehm, Norbert Pfeiffer, Katharina Bell
  • Patent number: 8476407
    Abstract: This application provides a metallopeptide catalyst comprising dirhodium bound to one or more carboxylate residues of a peptide, protein or peptidomimetic. These stable metallopeptides can achieve structure-selective protein modification though molecular recognition.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: July 2, 2013
    Assignee: William Marsh Rice University
    Inventors: Zachary Thomas Ball, Brian Vincent Popp, Alexander Nikolaevich Zaykov
  • Publication number: 20130160159
    Abstract: A replication inhibitor, which is an agent for inhibiting replication of a geminivirus, and comprises a zinc finger protein that can specifically bind to at least full length of stem loop region DNA of the geminivirus, or a part thereof, and can inhibit formation of a stem loop structure.
    Type: Application
    Filed: June 6, 2011
    Publication date: June 20, 2013
    Inventor: Takashi Sera
  • Publication number: 20130157335
    Abstract: The present invention relates to a biomemory device, comprising (a) a substrate; and (b) a heterolayer comprising a protein having a redox potential and an inorganic particle; wherein the heterolayer is immobilized on the substrate. By applying inorganic particles, the present invention provides a biomemory device capable of enhancing low current signals detected electron transfer between biomolecules and substrates up to at least five (5) times greater signals. The present invention is capable of controlling the redox states with help of redox potentials of proteins depending on applied potential. The present invention provides a new-concept biomemory device as an information storage device based on the principle of electron transfer of a naturally occurring biomolecule.
    Type: Application
    Filed: August 1, 2012
    Publication date: June 20, 2013
    Applicant: Industry-University Cooperation Foundation Sogang University
    Inventors: Jeong Woo Choi, Taek Lee, Jun Hong Min
  • Publication number: 20130084247
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Application
    Filed: July 30, 2012
    Publication date: April 4, 2013
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Tapas Das Gupta, Ananda Chakrabarty, Craig Beattie, Tohru Yamada
  • Patent number: 8409814
    Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 2, 2013
    Assignee: Life Technologies Corporation
    Inventors: Kurt Vogel, Rhonda Newman, Steven Riddle
  • Publication number: 20130078255
    Abstract: The application is based on the surprising finding that proteins regulated by increased c-myc activity in the liver can be used as sis and/or treatment monitoring of cancer and dysplasia, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC), and wherein the proteins are selected from a first group consisting of Polymeric immunoglobulin receptor, Phosphatidylinositol—glycan—specific phospholipase D, Alpha—fetoprotein, Antithrombin 3, Apolipoprotein E, Apolipoprotein M, Fibrinogen beta-chain, Haptoglobin, Paraoxonase 1, Retinol binding protein, Serum amyloid P- component, Transthyretin, or from a second group consisting of Afamin, Glutathione peroxidase 3, Hemopexin, Major urinary protein, Serine protease inhibitor A3K. Consequently, medical uses of said proteins, of corresponding compositions, of corresponding antibodies, of corresponding siRNA and of corresponding nucleotide sequences are claimed. Also claimed are corresponding kits and corresponding methods and procedures.
    Type: Application
    Filed: March 29, 2011
    Publication date: March 28, 2013
    Inventor: Jürgen Borlak
  • Publication number: 20130056211
    Abstract: Compositions and methods for making a composition comprising a polymer and one or more chelators covalently coupled to polymer, wherein the one or more chelators has a benzene ring with more than one hydroxyl group at any position that is free, or a derivative of the chelator, or a salt of the chelator and methods of use.
    Type: Application
    Filed: September 4, 2012
    Publication date: March 7, 2013
    Inventors: Cory Berkland, Zahra Mohammadi
  • Publication number: 20130052131
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Zhen Cheng, Kai Cheng
  • Publication number: 20130034893
    Abstract: Functionalized magnetic particles are emerging as a reliable and convenient technique in the purification of biomacromolecules (proteins and nucleic acids). We disclose a novel coupling procedure that can be used to create stable ferromagnetic nickel particles coated with Protein A for the affinity purification of antibody. The protein purification procedure is gentle, scalable, automatable, efficient and economical. By modifying the functional groups of amino acids in the protein coating, nickel particles can be used not only for affinity purification but for other sample preparation and chromatographic applications as well including nucleic acid isolations. The method can be easily modified for small and medium scale antibody purification in lab and pre-clinical research.
    Type: Application
    Filed: August 3, 2012
    Publication date: February 7, 2013
    Inventors: Zhiyu Li, Thomas Russell, Jun Gao
  • Publication number: 20130035471
    Abstract: The present invention relates to a new streptavidin muteins. This mutein is The muteins are capable of oligomerization to form tetramers, with relatively strong subunit interactions, dissociation constant (KD) for biotin in this mutein in the range of 10?7 to 10?8M, off-rate (koff) for the bound biotin in the streptavidin-biotin complex in the range of 10?4 sec?1, stable enough to allow reuse, and producible producable with reasonable production yield via secretion in a soluble functional state without the requirement of refolding streptavidin via the tedious and expensive denaturation and renaturation processes.
    Type: Application
    Filed: October 13, 2011
    Publication date: February 7, 2013
    Inventors: Sui-Lam Wong, Sau-Ching Wu, Isabelle Barrette-Ng, Ken Ng
  • Publication number: 20130029396
    Abstract: The present disclosure relates to a multifunctional biomemory device in which a protein having a redox potential substituted with a metal ion is directly immobilized on a substrate. The present disclosure provides an operating method in which the redox state of the protein is controlled by applying three different potentials. The present disclosure provides a biomemory device in which the metal ion of a metalloprotein is substituted to allow for artificial control of the redox potential. The present disclosure provides a new-concept biomemory device as an information storage device based on the principle of electron transfer of a naturally occurring biomolecule.
    Type: Application
    Filed: February 24, 2012
    Publication date: January 31, 2013
    Applicant: Industry-University Cooperation Foundation Sogang University
    Inventors: Jeong Woo Choi, Taek Lee, Jun Hong Min
  • Publication number: 20130029399
    Abstract: A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative.
    Type: Application
    Filed: April 6, 2011
    Publication date: January 31, 2013
    Applicants: YOSHIHIRO ISHIKAWA, IHI CORPORATION
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi, Hiroshi Sato
  • Publication number: 20130017155
    Abstract: The invention relates to a new tungsten-iron-Ferritin nanoparticle and uses thereof in imaging.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 17, 2013
    Inventors: Kevin Bennett, Simon Lubek, Maria Veronia Clavijo-Jordan
  • Publication number: 20130004431
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.
    Type: Application
    Filed: May 25, 2012
    Publication date: January 3, 2013
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty
  • Patent number: 8343911
    Abstract: The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: January 1, 2013
    Assignee: University of Iowa Research Foundation
    Inventors: Pradeep K. Singh, Michael J. Welsh, E. Peter Greenberg
  • Publication number: 20120329987
    Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.
    Type: Application
    Filed: August 28, 2012
    Publication date: December 27, 2012
    Applicant: University of Kansas
    Inventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
  • Publication number: 20120329176
    Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 27, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
  • Publication number: 20120302509
    Abstract: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Application
    Filed: July 23, 2012
    Publication date: November 29, 2012
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 8287850
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided. The conjugates are formed by a reductive amination reaction between at least one aldehyde group or keto group or hemiacetal group of the hydroxyalkyl starch or of a derivative of the hydroxyalkyl starch, and at least one amino group of the protein, so that the hydroxyalkyl starch or the derivative thereof is covalently linked to the protein via an azomethine linkage or a amino linkage. Methods of producing these conjugates and specific uses of the conjugates also are provided.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: October 16, 2012
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Michele Orlando, Norbert Zander, Harald S. Conradt, Frank Hacket, Klaus Langer, Ronald Frank
  • Publication number: 20120219504
    Abstract: The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.
    Type: Application
    Filed: November 3, 2010
    Publication date: August 30, 2012
    Applicants: SNU R&DB FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Nam-Hyuk Cho, Taek-Chin Cheong, Seung-Yong Seong, Ji Hyun Min, Jun Hua Wu, Young-Keun Kim
  • Patent number: 8247373
    Abstract: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 21, 2012
    Assignee: Agennix Incorporated
    Inventors: Jose Engelmayer, Atul Varadhachary
  • Patent number: 8247380
    Abstract: This invention characterizes the selective apoptotic activity of specially prepared zinc charged alpha 1-acid glycoprotein, alpha 2-HS glycoprotein, and alpha 1-antitrypsin. These proteins cause apoptosis in cancer cells while leaving normal cells intact. In addition, active fragments of zinc charged alpha 1-acid glycoprotein and alpha 2-HS glycoprotein, whether manufactured from the modification of natural alpha 1-acid glycoprotein or alpha 2-HS glycoprotein, recombinantly, or synthetically, selectively induce apoptosis.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: August 21, 2012
    Assignee: Ambryx Biotechnology, D.C.
    Inventor: David Tsai
  • Publication number: 20120208294
    Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.
    Type: Application
    Filed: July 16, 2010
    Publication date: August 16, 2012
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert Mcconnell
  • Publication number: 20120208213
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Application
    Filed: December 20, 2011
    Publication date: August 16, 2012
    Applicant: RANDOX LABORATORIES LIMITED
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20120196805
    Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.
    Type: Application
    Filed: February 27, 2012
    Publication date: August 2, 2012
    Inventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
  • Publication number: 20120190047
    Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 26, 2012
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
  • Publication number: 20120178183
    Abstract: Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 12, 2012
    Inventors: Garry P. Nolan, Erin F. Simonds, Sean C. Bendall
  • Publication number: 20120130053
    Abstract: A method of synthesizing ligand-conjugated gold nanoparticles (AuNPs) is disclosed. The method comprises: a) providing an amine-modified silica particle; b) providing a solution comprising Au+3 ions; c) suspending the amine-modified silica particle in the solution comprising Au+3 ions; d) allowing the Au3+ ions to be adsorbed and/or immobilized onto the surface of the amine-modified silica particle; e) exposing the Au3+ ions immobilized onto the surface of the amine-modified silica particle to radiation to obtain bare gold nanoparticles (AuNPs) adsorbed and/or immobilized onto the surface of the amine-modified silica particle, wherein the bare AuNPs are without organic surface modifications; and f) reacting a ligand with the bare AuNPs adsorbed and/or immobilized onto the surface of the amine-modified SiNP and thereby obtain ligand-conjugated gold nanoparticles (AuNPs).
    Type: Application
    Filed: May 17, 2011
    Publication date: May 24, 2012
    Applicant: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: CHIA-HUNG LEE, WEI-NENG LIAO, SHIH-HSUN CHENG, JEN-KUN CHEN, CHUNG-SHI YANG, LEU-WEI LO, YEU-KUANG HWU, FONG-SIAN LIN
  • Publication number: 20120116061
    Abstract: A method of selectively arraying ferritin and inorganic particles on a silicon oxide substrate at regions having vanadium, niobium or tantalum. An aspect of the method includes steps of: preparing a solution which contains ferritin modified at an N-terminal part of a subunit with a peptide set out in SEQ ID NO: 1, and from 0.01 v/v % to 10 v/v % of a nonionic surfactant and having a pH of from 7.4 to 8.2; and a binding step of bringing the solution in contact with regions of the substrate having vanadium, niobium, or tantalum to selectively array peptide-modified ferritin to vanadium, niobium or, tantalum portion. The method may also include a step of selectively arraying ferritin modified with the peptide set out in SEQ ID NO: 1, and the inorganic particles contained in ferritin at the vanadium, niobium, or tantalum portion by removing the solution.
    Type: Application
    Filed: November 18, 2011
    Publication date: May 10, 2012
    Applicant: Panasonic Corporation
    Inventor: Nozomu MATSUKAWA
  • Patent number: 8168763
    Abstract: Ferritin 2 is a tick secreted protein, which serves in the tick plasma as a non-heme iron transporter from the gut to the peripheral tissues. It can be exploited as an antigen for raising up host antibodies, which can reversely block this antigen in the tick and the attached tick will not have functional mechanism of the non-heme iron transport from the gut to the peripheral tissues. This mechanism is essential for the further tick development and its blocking eventually prevents transmission of tick-borne pathogens.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: May 1, 2012
    Assignee: Biology Centre AS CR, V.V.I.
    Inventors: Petr Kopacek, Ondrej Hajdusek
  • Publication number: 20120095185
    Abstract: An isolated conformational isomer of a bifunctional chelating agent of the formula (I): wherein the variables Q1 and Q2 are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.
    Type: Application
    Filed: September 20, 2011
    Publication date: April 19, 2012
    Applicant: NORDION (CANADA) INC.
    Inventors: Garry E. KIEFER, Cara L. Ferreira, Paul Jurek
  • Patent number: 8158579
    Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: April 17, 2012
    Assignee: BioRexis Pharmaceutical Corporation
    Inventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
  • Publication number: 20120077757
    Abstract: Disclosed herein are methods and composition for alteration of the presence, activity, or concentration of RNF138. Disclosed methods can be utilized to affect DNA double strand break repair. Methods and compositions can be utilized to alter RNF138 so as to prevent interaction between RNF138 and RAD51D. Specifically, methods can prevent RNF138-directed ubiquitylation of RAD51D, which is necessary for DNA double strand break repair.
    Type: Application
    Filed: May 11, 2011
    Publication date: March 29, 2012
    Applicant: UNIVERSITY OF SOUTH CAROLINA
    Inventors: Douglas L. Pittman, Brian D. Yard
  • Publication number: 20120065133
    Abstract: This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal.
    Type: Application
    Filed: March 4, 2010
    Publication date: March 15, 2012
    Inventor: P. Leslie Dutton
  • Publication number: 20120058565
    Abstract: Conjugates of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes with a variety of conjugating members are used in the formation of dinuclear metal complexes which bind to phosphate esters. By virtue of their conjugated forms, the complexes are incorporated into chromatographic media, affinity binding reagents, and dyes, which make the complexes useful in a wide range of assays, separations, and purifications. In addition, dinuclear metal complexes of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes that are not so conjugated are used in the detection of phosphate esters of biological species by either MALDI-TOF mass spectrometry or by dye displacement.
    Type: Application
    Filed: March 9, 2011
    Publication date: March 8, 2012
    Applicant: BIO-RAD LABORATORIES, INC.
    Inventors: Thomas R. Berkelman, Lisandra Martin, Rhiannon Jones, John Walker, II